Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06691243 · ClinicalTrials.gov registry record · Phase 2

Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV

A Phase 2 study of HIV and Cocaine Use Disorder, sponsored by University of Maryland, Baltimore.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
2
Study locations

NCT06691243 is a Phase 2 study of HIV and Cocaine Use Disorder that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 40 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06691243, a Phase 2 study of HIV and Cocaine Use Disorder, is actively recruiting participants, sponsored by University of Maryland, Baltimore.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this research study is to find out if semaglutide is safe and well tolerated in adults with cocaine use disorder who do and do not have human immunodeficiency virus (HIV). Participants will complete a screening process and if you are able to participate, you will be assigned to one of two treatment groups: semaglutide or placebo. Participants will: * Visit the clinic once a week for semaglutide or placebo injections * Visit the clinic once every two weeks for labwork, assessments and/or surveys * If consented to optional MRI's, complete two MRI's

Conditions Studied

HIV Cocaine Use Disorder

Interventions

  • DRUG Placebo
  • DRUG Semaglutide

Study Locations (2)

District of Columbia

  • Institute of Human Virology at the University of Maryland School of Medicine - Washington D.C.

Maryland

  • Institute of Human Virology at the University of Maryland School of Medicine - Baltimore

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-08-07
Est. Completion 2027-03
Phase Phase 2

Sponsor

University of Maryland, Baltimore

560 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06691243

The ClinicalTrials.gov registry entry for NCT06691243 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (91% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06691243 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Maryland.

Frequently Asked Questions

What is clinical trial NCT06691243 about?

NCT06691243 is a clinical study titled "Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV". The purpose of this research study is to find out if semaglutide is safe and well tolerated in adults with cocaine use disorder who do and do not have human immunodeficiency virus (HIV). Participants will complete a screening process and if you are able to participate, you will be assigned to one of...

What is the current status of trial NCT06691243?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-08-07. Estimated completion is 2027-03.

What conditions does trial NCT06691243 study?

This clinical trial studies the following conditions: HIV, Cocaine Use Disorder.

What interventions are being tested in trial NCT06691243?

The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).

Who is sponsoring clinical trial NCT06691243?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06691243 being conducted?

This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV

All registered trials for this condition

Cocaine Use Disorder

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.